Applied Computational Technologies Appoints a New CEO

Applied Computational Technologies Appoints a New CEO

Kathy Blum Will Help Drive the Commercialization of Company’s Cancer Therapy Product

PITTSBURGH, PA, June 16, 2008 - Applied Computational Technologies (AppCompTech) has announced the appointment of Kathy Blum as the company’s new Chief Executive Officer. With extensive experience in leading medical device, service and IT related businesses as well as global experience with start-ups and Fortune 50 organizations; Ms. Blum brings 27 years of industry knowledge and leadership with her as the new CEO of Applied Computational Technologies.

As CEO, Ms. Blum will be driving AppCompTech’s mission to provide advanced radiation oncology treatment planning with ProACTiveTM – the company’s groundbreaking software technology that is a dose calculation module which provides increased accuracy and greater speed in planning targeted radiation treatment.

“Ms. Blum will play a critical role in raising our final round of investment funding and positioning Applied Computational Technologies in the radiation therapy systems market,” says Jay McClatchey, AppCompTech Co-founder. “Our software blends incredible speed with accuracy, enabling adaptive planning for a significant competitive advantage over existing treatment technology. We are all looking forward to working together to complete testing and bring our product ProACTive to market.”

“In 2008 an estimated 1.4 million Americans will be diagnosed with cancer and approximately 65% of those cancer victims will receive some form of radiation therapy,” says Ms Blum. “I am honored to be part of an organization that is developing a product that can make radiation therapy more efficient and effective and help save more lives.”

In addition, AppCompTech has formed an important strategic partnership with D3 Radiation Planning, a UPMC affiliated radiation oncology service company that offers advanced radiation treatment planning to hospitals and freestanding institutions. D3 will play a critical role in the testing and clinical evaluation of ProACTive. Hospitals and freestanding institutions currently utilize D3 to provide their patients with advanced radiation therapy planning for Intensity Modulated Radiation Therapy (IMRT) and Image Guided Radiation Therapy (IGRT). D3 has performed tens of thousands of treatment plans for over 75 customers worldwide.

About Applied Computational Technologies

Applied Computational Technologies is a software development company focused on a life sciences application in Radiation Treatment Planning for Cancer Therapy. Applied Computational Technologies’ patented technology/software, called ProACTive™, shatters today’s industry-wide speed barrier to high accuracy dose calculation for radiation therapy. The company blends incredible speed with accuracy, enabling adaptive planning for a significant competitive advantage over existing treatment technology. www.appcomptech.com